These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17355951)

  • 1. Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies.
    Mimeault M; Batra SK
    Ann Oncol; 2007 Oct; 18(10):1605-19. PubMed ID: 17355951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.
    Mimeault M; Batra SK
    Pharmacol Rev; 2010 Sep; 62(3):497-524. PubMed ID: 20716670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications.
    Mimeault M; Batra SK
    Cancer Metastasis Rev; 2007 Mar; 26(1):203-14. PubMed ID: 17273942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence.
    Mimeault M; Batra SK
    Histol Histopathol; 2010 Aug; 25(8):1057-73. PubMed ID: 20552555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.
    Mimeault M; Batra SK
    Mol Med; 2011; 17(9-10):949-64. PubMed ID: 21607288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epithelial-mesenchymal transition in cancer progression].
    Gos M; Miłoszewska J; Przybyszewska M
    Postepy Biochem; 2009; 55(2):121-8. PubMed ID: 19824467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.
    Mimeault M; Batra SK
    Anticancer Agents Med Chem; 2010 Feb; 10(2):137-51. PubMed ID: 20184544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-mesenchymal transition in ovarian cancer.
    Vergara D; Merlot B; Lucot JP; Collinet P; Vinatier D; Fournier I; Salzet M
    Cancer Lett; 2010 May; 291(1):59-66. PubMed ID: 19880243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.
    Mimeault M; Batra SK
    Mol Aspects Med; 2014 Oct; 39():3-32. PubMed ID: 23994756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.
    Ahmed N; Abubaker K; Findlay J; Quinn M
    Curr Cancer Drug Targets; 2010 May; 10(3):268-78. PubMed ID: 20370691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of the epithelial-mesenchymal transition during tumor progression].
    Ansieau S; Caron de Fromentel C; Bastid J; Morel AP; Puisieux A
    Bull Cancer; 2010 Jan; 97(1):7-15. PubMed ID: 20026450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity.
    Voon DC; Wang H; Koo JK; Nguyen TA; Hor YT; Chu YS; Ito K; Fukamachi H; Chan SL; Thiery JP; Ito Y
    Stem Cells; 2012 Oct; 30(10):2088-99. PubMed ID: 22899304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.
    Mimeault M; Hauke R; Mehta PP; Batra SK
    J Cell Mol Med; 2007; 11(5):981-1011. PubMed ID: 17979879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
    Mimeault M; Batra SK
    Panminerva Med; 2008 Mar; 50(1):3-18. PubMed ID: 18427384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications.
    Miller SJ; Lavker RM; Sun TT
    Biochim Biophys Acta; 2005 Sep; 1756(1):25-52. PubMed ID: 16139432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile acid: a potential inducer of colon cancer stem cells.
    Farhana L; Nangia-Makker P; Arbit E; Shango K; Sarkar S; Mahmud H; Hadden T; Yu Y; Majumdar AP
    Stem Cell Res Ther; 2016 Dec; 7(1):181. PubMed ID: 27908290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.
    Mimeault M; Batra SK
    Gut; 2008 Oct; 57(10):1456-68. PubMed ID: 18791122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epithelial-mesenchymal Transition in Tumor Tissue and Its Role for Metastatic Spread of Cancer].
    Matějka VM; Fínek J; Králíčková M
    Klin Onkol; 2017; 30(1):20-27. PubMed ID: 28185461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic inhibition of Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell targets?
    Ruiz i Altaba A
    Cancer Cell; 2008 Oct; 14(4):281-3. PubMed ID: 18835029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.